Journal Mobile Options
Table of Contents
Vol. 46, No. 2, 2011
Issue release date: July 2011

Canthaxanthin Retinopathy: Long-Term Observations

Hueber A. · Rosentreter A. · Severin M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Purpose: To describe the long-term outcome of canthaxanthin retinopathy. Methods: We identified 13 patients with small golden particles near the macular region among a group of 35 patients with known consumption of canthaxanthin somewhen between 1983 and 1988. One long-term follow-up examination was possible in 5 of 13 cases after 16–24 years. The examinations included determination of visual acuity, the Amsler grid, slit lamp examination, perimetry, electro-oculography, electroretinography, optical coherence tomography and fluorescein angiography. Results: Complete disappearance of the golden particles took approximately 20 years. The patients in our study were asymptomatic and no functional defect related to canthaxanthin could be detected. Conclusions: Ingestion of canthaxanthin causes no long-term adverse effects.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Barker FM: Canthaxanthin retinopathy. J Toxicol Cutaneous Ocul Toxicol 1988;7:223–226.
  2. Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M, Boudreault G: Maculopathie en paillettes d’or. Can J Ophthalmol 1982;17:103–106.
  3. Arden GB, Barker FM: Canthaxanthin and the eye: a critical ocular toxicologic assessment. J Toxicol Cutaneous Ocul Toxicol 1991;10:115–155.
  4. Cortin P, Boudreault G, Rousseau AP, Tardif Y, Malenfant M: La rétinopathie à la canthaxanthine: 2. Facteurs prédisposants. Can J Ophthalmol 1984;19:215–219.
  5. Chang TS, Aylward W, Clarkson JG, Gass JD: Asymmetric canthaxanthin retinopathy. Am J Ophthalmol 1995;119:801–802.
  6. Bopp S, el-Hifnawi E, Laqua H: Canthaxanthin-retinopathie und macular pucker – klinisches Bild und ultrastruktuelle Befunde des macular pucker. Fortschr Ophthalmol 1989;86:456–460.
  7. Weber U, Goerz G, Baseler H, Michaelis L: Canthaxanthin-Retinopathie Verlaufskontrolle nach über 6 Jahren. Klin Monbl Augenheilkd 1992;201:174–177.
  8. Leyon H, Ros AM, Nyberg S, Algvere P: Reversibility of canthaxanthin deposits within the retina. Acta Ophthalmol (Copenh) 1990;68:607–611.
  9. Harnois C, Samson J, Malenfant M, Rousseau A: Canthaxanthin retinopathy. Anatomic and functional reversibility. Arch Ophthalmol 1989;107:538–540.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00